Skip to Content


In the US, Blinatumomab (blinatumomab systemic) is a member of the drug class miscellaneous antineoplastics and is used to treat Acute Lymphoblastic Leukemia.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Cytostatic agent

Antineoplastic agent: Monoclonal antibody

Chemical Name

Immunoglobulin scFv-scFv, anti-[Homo sapiensCD19 (B lymphocyte surface antigen B4, Leu-12)]/anti-[Homo sapiensCD3 epsilon (CD3E, Leu-4)] Mus musculusmonoclonal antibody bispecific single chain;Mus musculusscFv anti-CD19 [V-KAPPA (IGKV3-4-IGKJ1*01) [10.3.9 (WHO)

Foreign Names

  • Blinatumomabum (Latin)
  • Blinatumomab (German)
  • Blinatumomab (French)
  • Blinatumomab (Spanish)

Generic Names

  • Blinatumomab (OS: USAN)
  • MT-103 (IS)
  • UNII-4FR53SIF3A (IS)

Brand Names

  • Blincyto
    Amgen, Germany; Amgen, United Kingdom; Amgen, United States; Amgen Switzerland, Switzerland


ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.